Chemistry:Difluprednate
From HandWiki
Short description: Corticosteroid drug
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Durezol |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609025 |
| License data |
|
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H34F2O7 |
| Molar mass | 508.559 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Difluprednate, sold under the brand name Durezol, is a corticosteroid used for the treatment of post-operative ocular inflammation and pain.[1]
It was approved for medical use in the United States in June 2008.[1][2][3] It is available as a generic medication.[4]
Medical uses
Difluprednate is indicated for the treatment of inflammation and pain associated with ocular surgery; and the treatment of endogenous anterior uveitis.[1]
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis[5][6]
References
- ↑ 1.0 1.1 1.2 1.3 "Durezol emulsion". 11 July 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d07b65d5-f8e3-4594-a7fb-108218746cec.
- ↑ "Drug Approval Package: Durezol (Difluprednate) NDA #022212". 25 July 2008. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022212s000TOC.cfm.
- ↑ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
- ↑ "Competitive Generic Therapy Approvals". 29 June 2023. https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals.
- ↑ Clinical trial number NCT00501579 for "Study of Difluprednate in the Treatment of Uveitis" at ClinicalTrials.gov
- ↑ "Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study". Investigative Ophthalmology & Visual Science 55 (5): 2993–3002. May 2014. doi:10.1167/iovs.13-12660. PMID 24677110.
 |  |
